Retrospective multi-center study reports on ustekinumab effectiveness and safety in pediatric ulcerative colitis and unclassified disease, highlighting therapy utility.
Current data on ustekinumab therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBDU) are limited. We aimed to evaluate the effectiveness and safety of ustekinumab in pediatric UC and IBDU.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: